OBJECTIVES: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Although the condition is at present incurable, advances in the field of retinal implants demonstrate the progress now being made in combating the condition and restoring a measure of sight to those afflicted. The objective of this study was to assess the cost-effectiveness of first ever-commercial implant intended to restore some vision in the Retinitis Pigmentosa (RP) patients. METHODS: A multi -state transition Markov model was developed to determine the cost-effectiveness of retinal transplant versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%. RESULTS: The ICER for the retinal implant was €14,603 /QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively.  CONCLUSIONS: This economic evaluation shows that the retinal implant is a cost-effective intervention compared to usual care of the RP patients. The ICER for retinal implant falls below the published societal willingness to pay of EuroZone countries. Retinal implants could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to Retinitis Pigmentosa.